Clinical trials: Primary Open Angle Glaucoma
Primary Open Angle Glaucoma
OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma
To gain early evidence of safety and assess the effectiveness of the intraocular pressure (IOP)-lowering effectiveness of the OMNI 3.0 Surgical System in primary open-angel glaucoma (POAG).
- Trial name
- NCT06991270
- Testing
- OMNI 3.0 Surgical System
- Where
- Panama
- Volunteers
- 25 people
- Sponsor
- Sight Sciences, Inc.
Glaucoma, Primary Open Angle
Evaluation the Safety and Effectiveness of the GORE GDI in Adult Subjects With Primary Open-angle Glaucoma in Whom Previous Medical and Surgical Treatment Have Failed.
Evaluation the Safety and Effectiveness of the GORE GDI in Adult Subjects With Primary Open-angle Glaucoma in Whom Previous Medical and Surgical Treatment Have Failed.
- Trial name
- NCT07880132
- Testing
- GORE Glaucoma Drainage Implant
- Volunteers
- 70 people
- Sponsor
- Gore Ophthalmic
Primary Open Angle Glaucoma
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab interno (inside the eye) and ab…
- Trial name
- NCT06822738
- Testing
- XEN63 Glaucoma Treatment System
- Where
- 29 sites in United States
- Volunteers
- 130 people
- Sponsor
- AbbVie
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hypertension.
- Trial name
- BAHAMA (NCT07675824)
- Testing
- REGN22530
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- Regeneron Pharmaceuticals
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension
This study is to establish non-inferiority of a preservative free formulation of Bimatoprost ophthalmic solution 0.01% (YSBP) of YS Life Science Co., Ltd.
- Trial name
- NCT07661329
- Testing
- Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®)
- Where
- 22 sites in United States, India
- Volunteers
- 600 people
- Sponsor
- YS Life Science Co., Ltd.
Primary Open Angle Glaucoma
Hydrus® Microstent New Enrollment Post-Approval Study
The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation.
- Trial name
- CONFIRM (NCT04553523)
- Testing
- Hydrus Microstent, Cataract surgery, Monofocal IOL
- Where
- 22 sites in United States
- Volunteers
- 545 people
- Sponsor
- Alcon Research
Primary Open-Angle Glaucoma, Optic Nerve Injury
A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
This is a randomized, double-masked, placebo-controlled Phase II clinical trial. The primary objective is to explore the efficacy of G01 Eye Drops in the treatment of optic nerve injury associated with open-angle glaucoma…
- Trial name
- NCT07777861
- Testing
- G01 Eye Drops 100μg/ml, G01 Eye Drops 200μg/ml
- Where
- 9 sites in China
- Volunteers
- 90 people
- Sponsor
- Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.
Primary Open Angle Glaucoma
CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation
This study is intented to evaluate the safety, tolerability and preliminary efficacy of CRISPR/Cas9 Instantaneous Gene Editing Therapy (BD113 virus-like particle, also BD113vLVP) in patients with primary open-angle glaucoma…
- Trial name
- NCT06465537
- Testing
- BD113vVLP
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Primary Open Angle Glaucoma, Ocular Hypertension
Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population
The objective of this study is to evaluate the safety and effectiveness of Direct Selective Laser Trabeculoplasty (DSLT) in ethnic Chinese participants with Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT), or Normal…
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension, Normal Tension Glaucoma
- Trial name
- Zhuiguangzhe (NCT05902871)
- Testing
- External Automatic Glaucoma Laser, Direct Selective Laser Trabeculoplasty
- Where
- 2 sites in China, Singapore
- Volunteers
- 40 people
- Sponsor
- BelkinVision
Primary Open Angle Glaucoma (POAG)
A Real-World Evidence Study of Goniotomy With the C-REX™ Instrument in Patients With Primary Open Angle Glaucoma
This study enrolls adults with primary open angle glaucoma (POAG) who underwent goniotomy intraocular pressure (IOP)-lowering surgery with the C-Rex Instrument.
- Trial name
- CIRCLE (NCT06615661)
- Testing
- C-Rex Instrument
- Where
- 6 sites in United States
- Volunteers
- 100 people
- Sponsor
- Iantrek, Inc.
Primary Open Angle Glaucoma
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
The purpose of this study is to collect safety and performance data on the PRESERFLO™ MicroShunt XI in patients diagnosed with primary open angle glaucoma who are inadequately controlled on maximum tolerated medical therapy with…
- Trial name
- NCT07235592
- Testing
- Microshunt XI
- Where
- 11 sites in Austria, Belgium and 6 more
- Volunteers
- 112 people
- Sponsor
- Santen SAS
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension
Dorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECH
The primary objective of this study is to evaluate the ocular surface safety of an ophthalmic solution indicated for the management of glaucoma, containing the active ingredients dorzolamide, timolol, and brimonidine, in patients…
- Trial name
- GLAUCO-TECH (NCT07690397)
- Testing
- Preservative-free dorzolamide-timolol-brimonidine combination, Preservative dorzolamide-timolol-brimonidine combination
- Where
- Colombia
- Volunteers
- 140 people
- Sponsor
- Tecnoquimicas
Primary Open Angle Glaucoma, Cataract
A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX)
A study to assess the safety of the Helix Surgical System in cataract surgery and to gain early evidence of its effectiveness in lowering intraocular pressure (IOP) in subjects with mild to moderate primary open-angle glaucoma…
- Trial name
- HELIX (NCT06948773)
- Testing
- Helix Surgical System
- Where
- Panama
- Volunteers
- 25 people
- Sponsor
- Sight Sciences, Inc.
Glaucoma, Primary Open Angle
Excimer Laser Trabeculostomy Glaucoma Treatment Study
Evaluation of the safety and effectiveness of the ELIOS System procedure to reduce intraocular pressure (IOP) in adult subjects with mild to moderate primary open-angle glaucoma (POAG) undergoing cataract surgery
- Trial name
- ELTGTS (NCT04899063)
- Testing
- ELIOS Procedure
- Where
- 20 sites in United States
- Volunteers
- 318 people
- Sponsor
- Elios Vision, Inc.
Glaucoma, Primary Open Angle
Safety and Feasibility of the ELIOS System in POAG Patients
Evaluation of the safety and effectiveness of the ELIOS System procedure to reduce intraocular pressure (IOP) in adult subjects with mild to moderate primary open-angle glaucoma (POAG)
- Trial name
- NCT05999006
- Testing
- ELIOS Procedure
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Elios Vision, Inc.
Ocular Hypertension, Primary Open Angle Glaucoma
Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle Glaucoma
This study aims to evaluate the safety and efficacy of DNN.31.19.026 compared with Cosopt® for the treatment of ocular hypertension or primary open-angle glaucoma.
- Trial name
- RENOIR (NCT07617532)
- Testing
- Product DNN.31.19.026, COSOPT®
- Volunteers
- 336 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Primary Open-Angle Glaucoma (POAG)
GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma
This is an investigator initiated, single center, open label, non-randomized, exploratory clinical study. The purpose is to assess the safety and preliminary efficacy of gene therapy GVB-2001 (ScAAV2-dnRhoA) delivered via…
- Trial name
- NCT06921317
- Testing
- GVB-2001-high dose, GVB-2001-low dose
- Where
- China
- Volunteers
- 6 people
- Sponsor
- IVIEW Therapeutics Inc.
Glaucoma, Primary Open Angle Glaucoma
Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma
Glaucoma is a progressive optic neuropathy with retinal ganglion cell loss which leads to visual field loss. Open-angle glaucoma is the most common form of glaucoma.
- Conditions
- Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigment Dispersion Glaucoma
- Trial name
- TES-GPS (NCT06682962)
- Testing
- Transcorneal electrical stimulation (TES) with the OkuStim 2 System
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Okuvision GmbH
Primary Open-angle Glaucoma
GORE Glaucoma Drainage Implant Clinical Study Dominican Republic
The objective of this early feasibility clinical study is to evaluate the safety and effectiveness of several different GORE Glaucoma Drainage Implant configurations in subjects with primary open-angle glaucoma that is…
- Trial name
- NCT05557058
- Testing
- Gore Glaucoma Device Implant (GORE GDI)
- Where
- Dominican Republic
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- W.L.Gore & Associates
Primary Open Angle Glaucoma
Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma
It is an interventional study for the treatment of Primary Open-Angle Glaucoma (POAG) using the Hexiris Microinvasive Scleral Trephine (MIST) system. This medical device includes a sclerectomy punch and injector assembly.
- Trial name
- NCT07358650
- Testing
- Hexiris Microinvasive Scleral Trephine (MIST)
- Where
- 5 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Hexiris Inc